#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chondrosarcoma Chondrosarcoma metastatic Hyperadrenocorticism Depression Angelman's syndrome Bladder cancer Systemic candida Dermatitis Central nervous system neoplasm Congenital pseudarthrosis B-cell lymphoma refractory Measles Nephropathy Malformation venous Ovarian cancer More trials…

    Learn about Rare Diseases

    Primary immunodeficiency syndrome – Trials in Disease X-linked lymphoproliferative syndrome Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Treatment Hereditary neuropathic amyloidosis – Life with Disease Metachromatic leukodystrophy – Life with Disease KBG syndrome – Trials in Disease Andersen-Tawil syndrome – Life with Disease Niemann-Pick disease – Basic Information Hereditary motor and sensory neuropathy – Trials in Disease Bronchopulmonary dysplasia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Furosemide Ph. Eur. Odronextamab Enx-101 Interleukin-1 Trifluridine Cldn6 Car-T Metoprolol Tartrate Doxylamine Hydrogen Succinate Pitavastatin Calcium ETX-19477 Casimersen Vanglusagene Ensiparvovec Ag-946 Phosphate Paroxetine Hydrochloride Erlotinib Bicalutamide Minocycline Hydrochloride Cholesterol Satralizumab Transcon Il-2Β/Γ More therapies…

    Learn about Your Condition

    Substance use disorder Cholecystitis acute Rheumatoid arthritis Kearns-Sayre syndrome Colon cancer stage II Tricuspid valve disease Plasma cell leukaemia Muscle injury Peripheral artery restenosis Cardiomyopathy Neuroendocrine carcinoma Small intestine carcinoma Neurodegenerative disorder Anal cancer Colour blindness More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vitiligo

  • Efficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo

    Recruiting

    2 1
    Investigated Diseases:
    • Vitiligo
    Belgium Poland

  • A Study Testing Zasocitinib Compared to Placebo in Adults with Nonsegmental Vitiligo to See How Well It Works and How Safe It Is

    Recruiting

    2 1
    Investigated Diseases:
    • Vitiligo
    Investigated Drugs:
    • Zasocitinib
    France Italy Poland Spain

  • Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

    Recruiting

    3 1
    Investigated Diseases:
    • Vitiligo
    Investigated Drugs:
    • Ruxolitinib
    Austria Belgium Bulgaria Denmark France Germany +6

  • Study of Ritlecitinib Combined with Narrow Band UVB Light Therapy Compared to Ritlecitinib Alone in Adults with Vitiligo

    Recruiting

    2 1 1 1
    France

  • Study on Anifrolumab and Phototherapy for Adults with Progressive Vitiligo

    Recruiting

    2 1 1
    Investigated Diseases:
    • Vitiligo
    Investigated Drugs:
    • Anifrolumab
    France

  • Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

    Recruiting

    3 1 1
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    • Povorcitinib
    Austria Belgium Bulgaria Czechia Denmark France +7
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!